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Background: Endometrial cells, which are shed by retrograde menstruation, may aberrantly express molecules
involved in invasion and migration, leading to endometriosis. The aim of this study was to investigate the
expression of the laminin gamma 2 chain (LAMC2) in the tissues of women with and without endometriosis.
Methods: Endometrial biopsy specimens were collected from healthy volunteers and from endometriosis patients.
Biopsy specimens from the corresponding endometriotic lesions were also collected. The expression of laminin
gamma 2 chain was evaluated by immunohistochemistry and reverse transcription polymerase chain reaction
(RT-PCR).
Results: Endometrial tissue from women with or without endometriosis showed constitutive expression of LAMC2
mRNA throughout the menstrual cycle. A higher mRNA level was observed in ectopic endometrium (Ec) from
women with endometriosis compared with eutopic endometrium (Eu) from women with endometriosis.
Immunohistochemistry revealed a varied pattern of laminin gamma 2 chain expression, with increased epithelial
expression in eutopic endometrium from women with endometriosis compared with those without endometriosis.
Conclusions: The altered expression of laminin gamma 2 chain in eutopic endometrium from women with
endometriosis may provide new opportunities for diagnosis and treatment.
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Endometriosis is a common benign, hormone-dependent
gynaecological disease that is characterised by the pres-
ence and growth of endometrial tissue outside the uterus.
The most widely accepted theory is that retrograde men-
struation through the fallopian tube leads to the transfer
of endometrial cells into the peritoneal cavity, where they
become embedded in the pelvic structures [1] (for a re-
view, see [2]). However, this theory does not explain why
more than 80% of women of reproductive age experience
retrograde menstrual bleeding but do not develop endo-
metriosis. Currently, a combination of many theories,
including immunological defects, genetic predisposition
and epigenetic modifications, could provide possible* Correspondence: c.munaut@ulg.ac.be
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reproduction in any medium, provided the orexplanations as regarding the cause of the disease. Never-
theless, the adhesion, invasion and proliferation of ectopic
endometriotic cells are all necessary for the establishment
of endometriotic lesions. Notably, endometriotic cells are
histologically benign but display invasive characteristics.
Laminin-332 (LN-332, previously termed laminin-5),
also referred to as kalinin, nicein and epiligrin, consists
of alpha 3, beta 3 and gamma 2 chains, which represent
the products of three distinct genes (LAMA3, LAMB3
and LAMC2, respectively). LN-332 is a laminin isoform
that is a major adhesive component of epidermal base-
ment membranes [3,4]. In vitro, LN-332 promotes the
attachment, spreading, scattering and migration of non-
tumorigenic epithelial cells [5,6]. LN-332 also stimulates
human tumour cells to form lamellipodia, leading to
enhanced cell migration and invasion [7]. Immunohisto-
chemical studies have shown that LN-332 (or its sub-
units) is highly expressed in various types of humantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expressed in tumour cells at the invasion front or in
budding tumour cells in many types of human cancers
such as adenocarcinoma of the colon, breast, pancreas
and lung, squamous cell carcinoma and melanoma [8,9].
Because endometriosis is characterised by the acquisi-
tion of malignant properties, such as the ability to invade
surrounding tissue and disseminate to ectopic sites, the
aim of the present study was to investigate the expres-
sion of the laminin gamma 2 chain in the tissues of
women with and without endometriosis.Methods
Sample collection
Endometriotic lesions (Ec) were removed from women
(n = 25, aged 28–50 years, mean age 35.4 ± 4.8 years)
undergoing laparoscopy for pain or infertility (Table 1). All
the women had normal documented ovulatory cycles as
well as normal endocrine parameters and did not receive
hormone therapy or take oral contraception for at least
3 months before surgery. Simultaneously, eutopic endo-
metrium was obtained from the same women (EuE+).
Normal endometrial tissues (EuE-) were collected from
healthy non-menopausal women (n = 27, aged 20–45 years,
mean age 39.2 ± 7.9 years) with spontaneous, regular men-
strual cycles (26–33 days) who were undergoing laparo-
scopic surgery for benign gynaecologic indications (tubal
ligation, ovarian cystectomy or hysterectomy).
All endometrial biopsy samples were obtained with a
Cornier Pipelle suction curette (C.C.D. International,
Paris, France), which allows sampling of the functional
layer of the endometrium. All samples were classified
according to classical histologic criteria [10].
Patients provided informed consent, and the Institu-
tional Review Board of the University of Liège approved
the collection and use of human tissue.Table 1 Patient characteristics
IHC
Disease-free
N° of patients 27
Proliferative phase 12
Secretory phase 15




N° of patients with more than one lesion
Deep endometriosis
Ovarian endometriosis
Peritoneal endometriosisReverse transcription-polymerase chain reaction (RT-PCR)
analysis
For gene expression analysis, endometrial biopsy speci-
mens were collected from healthy volunteers (EuE-: pro-
liferative phase, n = 12; secretory phase, n = 15) and from
endometriosis patients (EuE + and Ec, n = 9) (Table 1).
After surgical resection, the tissue samples were immedi-
ately frozen in liquid nitrogen. The frozen tissues were
processed as previously described [11]. The specific
primers (Eurogentec, Liège, Belgium) for LAMC2 mRNA
were 5′-AAAGCCACGTTGAGTCAGC-3′ (forward) and
5′-TCTTCCACCTGAAAGGACTGAT-3′ (reverse). The
specific primers for 28S rRNA were 5′-GTTCACCC
ACTAATAGGGAACGTGA-3′ (forward) and 5′-GGAT
TCTGACTTAGAGGCGTTCAGT-3′ (reverse). RT-PCR
was performed using 10-ng aliquots of cDNA, Taq
polymerase (Takara, Shiga, Japan) and 5 pmol of each
primer. The specific PCR products were resolved on
10% polyacrylamide gels (Bio-Rad) and analysed with a
luminescent image analyser (LAS-4000, Fujifilm) after
GelStar staining (Lonza Rockland, Inc., Rockland, ME).
The LAMC2 mRNA levels were expressed as ratios of
the 28S rRNA as previously reported [12].
Immunohistochemistry
Tissue samples were fixed in 4% formalin for 4–12 hours,
embedded in paraffin and cut into 4-μm sections. The
sections were mounted on SuperFrost Plus glass slides
(Menzel-Gläser, Braunschweig, Germany), dewaxed in xy-
lene, rehydrated and subsequently autoclaved for 11 min at
126°C and 1.4 bar in Target Retrieval Buffer (S2031 for lam-
inin gamma 2 chain; DakoCytomation, Glostrup, Denmark)
or treated with proteinase K (S3004 for cytokeratin 7 and
S1699 for Ki-67; DakoCytomation, Glostrup, Denmark).
Endogenous peroxidases were blocked by treatment with
3% H2O2/H2O for 20 min, and non-specific binding was













Figure 1 RT-PCR analysis of LAMC2 mRNA expression. LAMC2
mRNA levels in normal endometrium (A). Paired LAMC2 mRNA
expression in eutopic (Eu) and ectopic (Ec) endometrium from
women with endometriosis (B). Comparison of LAMC2 mRNA
expression in eutopic endometrium from women without
endometriosis (EuE-) and eutopic endometrium from women with
endometriosis (EuE+) (C). P and S indicate normal proliferative and
secretory endometrium, respectively. * P < 0.05.
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were incubated with the following primary antibodies:
laminin gamma 2 chain (Dako, M7262, diluted 1:25),
cytokeratin 7 (BD Biosciences, 345779, ready-to-use) and
Ki-67 (Dako, M7240, diluted 1:100). The sections were
washed in PBS and subsequently incubated for 30 min with
EnVision +HRP (K4001, Dako) or biotinylated goat anti-
mouse antibodies (Dako E0433, diluted 1:400) followed by
incubation with peroxidase-labelled streptavidin for 30 min
(Dako P0397, diluted 1:500). Staining was detected with
3,3′-diaminobenzidine (DAB) chromogen. The nuclei were
counterstained by incubation with haematoxylin for 2 min.
The sections were mounted, examined and photographed.
The negative control samples were processed by omitting
the primary antibody or by incubating the sections with
nonspecific IgG at the same concentration as the primary
antibody. Placenta was used as a positive control.
Immunohistochemistry scoring
Immunohistochemical staining analysis was semi-
quantitative. The intensity of staining was characterised
as follows: no staining (0), weak but detectable (1),
strong (2) or very strong (3). The percentage of positive
glands was graded as follows: no positive glands (0), less
than 11% (1), 11-50% (2), 51-80% (3) or greater than
80% (4). The final score was calculated by multiplying
the two scores.
Statistical analyses
The patient groups were compared using the Kruskal-
Wallis test, and significant differences were further
analysed via pairwise comparisons using the Mann–
Whitney test. The results are presented as medians ±
quartiles (25th-75th percentile). P values < 0.05 were
considered statistically significant.
Results
Laminin gamma 2 mRNA expression
LAMC2 mRNA was detectable in the endometrium of
women without endometriosis, and no differences were
observed between the proliferative and secretory phases
of the menstrual cycle (Figure 1A). When RT-PCR was
performed in paired samples of ectopic and eutopic
endometrium of women with endometriosis, an up to 3
fold increase of LAMC2 mRNA levels was detected in
the ectopic endometrium (Figure 1B, P < 0.05). Similar
LAMC2 mRNA levels were observed in the eutopic
endometrium of women with and without endometriosis
(Figure 1C).
Laminin gamma 2 immunoreactivity in ectopic
endometrium
Laminin gamma 2 expression was first investigated in
ectopic endometrium (Figure 2A). Endometriotic lesionswere confirmed and localised via cytokeratin 7 immuno-
detection, as illustrated in Figure 2B. To assess the
proliferative status of the endometrial glands, Ki-67 im-
munoreactivity was also examined in serial sections, as
illustrated in Figure 2C. Staining with antibody against lam-
inin gamma 2 revealed a cytoplasmic expression pattern
exclusively localised in epithelial cells. In endometriotic
Figure 2 Representative immunohistochemistry images. For the
laminin gamma 2 chain (A), cytokeratin 7 (CK7, B) and Ki-67 (C) in
serial sections of endometriosis lesions. Scale bar = 1 mm.
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appeared in the cytoplasm of epithelial cells, either
distributed along the basement membrane or with a
more uneven distribution as illustrated in Figure 3A-C.
In areas of desquamation, the epithelial cells of the dis-
persing glands displayed a highly intensified intracyto-
plasmic immunoreactivity (Figure 3A), whereas laminin
gamma 2 was detected in a more linear pattern along
the basement membranes of intact glands (Figure 3B).
In pluristratified glands, laminin gamma 2 chain immu-
noreactivity was more irregular (Figure 3C).Laminin gamma 2 immunoreactivity in eutopic
endometrium from women with and without
endometriosis
Positive staining for the laminin gamma 2 chain was ob-
served in epithelial basement membranes around individ-
ual glands and in the basement membranes underlying
the endometrial surface epithelium (Figure 3D-F) in the
eutopic endometrium of women with endometriosis. In
normal eutopic endometrium, a similar cytoplasmic ex-
pression pattern was observed in the glandular epithelium;
however, in a few cases, stronger expression was observed
in the apical region of the epithelium (Figure 3G-I). Lam-
inin gamma 2 was not observed in the stromal cells. There
was no significant variation in immunoreactivity between
the different menstrual phases.
Semi-quantitative evaluation of laminin gamma 2
To compare laminin gamma 2 expression in the ectopic
and eutopic endometrium, we evaluated the percentage
of positive glands in each tissue (Figure 4A). No differ-
ences were noted between eutopic and ectopic endome-
tria from patients with endometriosis (76.4% ± 7.5%
versus 88.3% ± 6.2%); however, in patients without endo-
metriosis, the endometrium displayed the lowest percent-
age of laminin gamma 2 chain-expressing glands (30.1% ±
9.3%, P < 0.001). To better compare the intensity of lam-
inin gamma 2 chain expression in different tissues, a
semi-quantitative scoring method was performed using
whole tissue sections as described above (see Methods).
When we evaluated only the intensity of laminin gamma 2
staining in positive glands from the different tissues, no
differences between the groups were observed; however,
eutopic endometrium from women without endometriosis
exhibited a null score more frequently than eutopic and
ectopic endometrium from patients with endometriosis
(Figures 3G and 4B). In other words, when glands were
positive in EuE-, their intensity was lower than that of
positive glands in EuE+. When a global scoring method
was applied that considered both the number of positive
glands and their intensity, no differences were observed
between ectopic and eutopic endometrium in patients
with endometriosis. However, endometrium from patients
without endometriosis displayed a reduced global expres-
sion score compared either with eutopic endometrium
from patients with endometriosis; either with ectopic
endometrium (Figure 4C, P < 0.005).
Discussion
In this study, LAMC2 mRNA was found to be differen-
tially expressed in the ectopic endometrium of women
with endometriosis compared with their eutopic endomet-
rium (Figure 1B). The role of the laminin gamma 2 chain
in the pathogenesis of endometriosis has not been previ-
ously evaluated, although some studies have implicated
Figure 3 Representative immunohistochemistry images for laminin gamma 2 chain expression. Sections of ectopic endometrium (Ec,
A-C), eutopic endometrium from women with endometriosis (EuE+, D-F) and eutopic endometrium from women without endometriosis (EuE-,
G-I) are shown. G illustrates a negative control. Arrows indicate weakly positive glands. Arrowheads indicate negative glands. Scale bar = 100 μm.
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we hypothesised that laminin gamma 2 chain could also
play a role in the adhesion, migration and invasion of
endometrial cells, which are required for the development
of endometriosis [13]. Laminin was previously found to be
expressed in the glands and stroma of eutopic and ectopic
endometrium however, the type of laminin investigated
was unclear [14,15]. Recently, altered expression of the
LAMC1 gene was described in the endometrium of
patients with endometriosis (compared with healthy endo-
metrium) [16]. The specific expression of the laminin
gamma 2 chain has not been evaluated in human endo-
metriosis; however, the laminin gamma 2 chain was re-
cently described as being strongly associated with the
initiation of endometriosis in a mouse model [17].
Endometriosis is a benign disease, although cells from
endometriotic tissue and cancer cells share the ability to
spread into and invade adjacent tissue. The molecular
mechanisms that drive endometriosis cells to target other
tissues are largely unknown. Our present data suggest that
the laminin gamma 2 chain could be involved in the inva-
sive activity of endometriotic cells as it has been found in
the majority of ectopic endometrial glands.The comparison of laminin gamma 2 chain expres-
sion in eutopic endometrium from patients without or
with endometriosis also revealed significant differences
(Figure 4C). The global expression score was significantly
lower in eutopic endometrium from patients without
endometriosis due to the number of positive glands and
their intensity. Indeed, the eutopic endometrium of
women without endometriosis more often displayed
weaker glandular expression of the laminin gamma 2
chain. However, when analysing LAMC2 mRNA levels,
we did not observe differences between eutopic endomet-
rium from women with and without endometriosis
(Figure 1C). One possible explanation for this result could
be that the mRNA analysis was performed only on a lim-
ited number of RNA samples from the eutopic endomet-
rium of women suffering from endometriosis (n = 9),
whereas for protein analysis, a greater number of patients
were analysed (n = 25). The differences between gene and
protein expression could also be explained by post-
transcriptional modification of mRNA and mature protein
as well as protein degradation [18,19]. Alternatively, small
non-coding RNAs such as miRNAs, which are essentially
translational repressors, could be involved in this process
Figure 4 Quantification of laminin gamma 2 chain expression
in glands. (A), evaluation of the intensity of expression (B) and the
global score (C). Ec indicates ectopic endometrium, EuE + indicates
eutopic endometrium from women with endometriosis, and EuE-
indicates eutopic endometrium from women without endometriosis.
** P < 0.001.
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conditions can contribute to increases in the amount of
protein translated from a given target mRNA without al-
tering the amount of RNA.
The facts that the laminin gamma 2 chain was expressed
unevenly and that its expression was interrupted at some
points could facilitate epithelial cell motility. Our results
are in agreement with a previous study showing that the
laminin gamma 2 chain and the alpha 3 beta 1 integrinreceptor could be involved in the mechanism of endomet-
riosis [22].
Numerous studies using immunohistochemistry and in
situ hybridisation have shown that the laminin gamma 2
chain is localised at the leading edge of invading carcin-
omas and that its expression is positively correlated with
invasiveness and patient survival [23]. However, other
studies have shown that the expression of LN-332 is
reduced during the progression of human carcinomas,
and its expression is associated with lower invasive and
metastatic activity [24,25]. This discordance can be
explained by the overexpression of the laminin gamma 2
chain monomer in tumour cells, as the laminin alpha 3
and/or beta 3 chains are often decreased or impaired in
these cells [26-28]. We have previously shown that the
acquisition of a migratory phenotype in epithelial cells
in vitro is associated with the overexpression of MT1-
MMP, which can participate in the pericellular degrad-
ation of the laminin gamma 2 chain monomer deposited
by the migratory cells themselves, thereby providing a
modified substrate that promotes cell migration [29].
Differential laminin gamma 2 chain localisation and ex-
pression levels have been shown to be of prognostic
value in colorectal [9], pancreatic [25] and lung adeno-
carcinomas [27] as well as gastric cancer [26]. The
serum concentrations of laminin gamma 2 fragments
are also useful for assessing the treatment results and
clinical courses of patients with head and neck squa-
mous cell carcinoma [30]. A weakness of our study is
that sera from patients with and without endometriosis
were not collected with the tissue samples.Conclusions
In conclusion, our study showed that the laminin
gamma 2 chain is a normal component of the eutopic
endometrium of women with and without endometri-
osis. The increased expression of the laminin gamma 2
chain in eutopic endometrium from women with endo-
metriosis suggests a possible role for this protein in
endometrial cell adhesion and, consequently, in the de-
velopment of endometriosis. Laminin gamma 2 chain
expression by normal endometrial cells during retro-
grade menstruation could contribute to their peritoneal
anchoring.
Although the underlying mechanisms that lead to the
development of endometriosis are not fully understood,
our data indicate that the glandular cells in eutopic
endometrium may phenotypically differ between women
with endometriosis and disease-free women.
The altered expression of laminin gamma 2 chain in
eutopic endometrium from women with endometriosis
might provide new opportunities for diagnosis and treat-
ment in the future.
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